Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Interferon alfa-n1 is a purified form of human interferon used to stimulate the innate antiviral response in the treatment of genital warts due to human papilloma virus. Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated.
- Mechanism
- Curator reviewed
Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.
- Primary indication
- For the treatment of venereal or genital warts caused by the Human Papiloma Virus.Curator reviewed
- Formula / weight
- C860H1353N227O255S9 · 19241.1 Da
- First approval
- Canada, 1992
- Also known as
- Interferon alpha-n1 (INS) · WELL-FERON · WELLFERON
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Interferon alfa-n1, and which of those have an active Phase 3 trial?